ADS-5102 is initially being developed by Adamas for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. ADS-5102, an investigational agent, is a long-acting, extended-release capsule
The results are highlighted today in a poster presentation titled, "Novel oral RORgamma agonists demonstrate anti-tumor efficacy in the 4T1 breast cancer model," with lead author, Jacques Moisan,
These funds represent the first closing of a Series B venture financing round, the proceeds from which will be used to advance a series of clinical programs and
The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one stop shopping and joint expertise in
The patent protects the improved modular design of EnWave’s nutraREV machinery, which is the most commercially advanced platform in the Company’s technology portfolio. EnWave has sold or received
Based on the results of this study (DRM04-HH02) and its first Phase 2b study (DRM04-HH01), Dermira plans to initiate a Phase 3 program for DRM04 in axillary hyperhidrosis
The conclusions remark that the patients treated with chondroitin sulfate achieved statistically significantly and clinically meaningful better pain and functional capacity scores. This drug also has improved safety
BREO ELLIPTA is a fixed dose combination of the inhaled corticosteroid, fluticasone furoate (FF) and the long-acting beta2 agonist (LABA), vilanterol (VI), administered using the ELLIPTA inhaler. The
The facility, which is expected to come online in early 2016, will support Juno’s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno’s pipeline, and the company’s
In addition, the Russian Patent Office issued a first notification to grant patent coverage of the Company’s lead therapeutic candidate, NNI-351, for pharmaceutical composition and a method of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.